Tenaya Therapeutics (TNYA) Net Cash Flow (2020 - 2026)

Tenaya Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$19.7 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 139.76% year-over-year to -$19.7 million in Q1 2026; TTM through Mar 2026 was $27.1 million, a 567.98% increase from a year earlier, with the FY2025 full-year figure at $96.2 million, up 331.19% from the prior year.
• Net Cash Flow eased to -$19.7 million in Q1 2026 per TNYA's latest filing, from $44.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $60.8 million in Q4 2022 and bottomed at -$49.9 million in Q3 2024.
• The 5-year median for Net Cash Flow is $3.0 million (2023), against an average of $2.5 million.
• Across the five-year window, Net Cash Flow plunged 12587.63% in 2022 and jumped 1231.91% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $60.8 million in 2022, then sank by 160.01% to -$36.5 million in 2023, then surged by 89.28% to -$3.9 million in 2024, then soared by 1231.91% to $44.2 million in 2025, then slumped by 144.44% to -$19.7 million in 2026.
• Per Business Quant, the three latest TNYA Net Cash Flow figures stand at -$19.7 million (Q1 2026), $44.2 million (Q4 2025), and -$6.4 million (Q3 2025).